Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonists and TxSIs.
A series of compounds (22-36) which possess dual-acting PAF antagonist/TxSI have been generated by the approach of linking the known PAF antagonists and TxSIs, such as Ridogrel (1).
Fujita
Masakazu
M
Omiya Research Laboratory, Nikken Chemicals Co., Ltd., Kitabukuro-cho, Saitama-shi, Saitama 330-0835, Japan. souyaku@jade.dti.ne.jp
Seki
Taketsugu
T
Inada
Haruaki
H
Shimizu
Kazuhiro
K
Takahama
Akane
A
Sano
Tetsuro
T
D000818:Animals; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000737:chemistry*; D006801:Humans; D066298:In Vitro Techniques; D007202:Indicators and Reagents; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000737:chemistry*; D010980:Platelet Membrane Glycoproteins / Q000037:antagonists & inhibitors* / Q000737:chemistry; D011817:Rabbits; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; D013329:Structure-Activity Relationship; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors* / Q000737:chemistry
D004791:Enzyme Inhibitors; D007202:Indicators and Reagents; D010975:Platelet Aggregation Inhibitors; D010980:Platelet Membrane Glycoproteins; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; C039351:platelet activating factor receptor; D013930:Thromboxane-A Synthase